PROCEPT BioRobotics Corporation (PRCT)
NASDAQ: PRCT · Real-Time Price · USD
20.89
+1.14 (5.77%)
At close: Jul 10, 2026, 4:00 PM EDT
20.48
-0.41 (-1.96%)
After-hours: Jul 10, 2026, 6:33 PM EDT
PROCEPT BioRobotics Revenue
PROCEPT BioRobotics had revenue of $83.13M in the quarter ending March 31, 2026, with 20.20% growth. This brings the company's revenue in the last twelve months to $322.02M, up 29.26% year-over-year. In the year 2025, PROCEPT BioRobotics had annual revenue of $308.05M with 37.22% growth.
Revenue (ttm)
$322.02M
Revenue Growth
+29.26%
P/S Ratio
3.69
Revenue / Employee
$362,640
Employees
888
Market Cap
1.19B
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 308.05M | 83.56M | 37.22% |
| Dec 31, 2024 | 224.50M | 88.31M | 64.84% |
| Dec 31, 2023 | 136.19M | 61.18M | 81.55% |
| Dec 31, 2022 | 75.01M | 40.54M | 117.60% |
| Dec 31, 2021 | 34.47M | 26.76M | 346.72% |
| Dec 31, 2020 | 7.72M | 1.55M | 25.09% |
| Dec 31, 2019 | 6.17M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AdaptHealth | 3.29B |
| QuidelOrtho | 2.66B |
| Integra LifeSciences Holdings | 1.64B |
| CONMED | 1.37B |
| Lumexa Imaging Holdings | 1.03B |
| Tandem Diabetes Care | 1.03B |
| Avanos Medical | 715.90M |
| Bioventus | 576.30M |
PRCT News
- 9 days ago - Procept BioRobotics downgraded to Hold from Buy at Truist - TheFly
- 12 days ago - PROCEPT BioRobotics Slides: Conference presentation - Filings
- 17 days ago - Procept BioRobotics initiated with an Outperform at Evercore ISI - TheFly
- 4 weeks ago - Leerink downgrades Procept BioRobotics to Market Perform, lowers target to $29 - TheFly
- 4 weeks ago - Procept BioRobotics downgraded to Market Perform from Outperform at Leerink - TheFly
- 5 weeks ago - PROCEPT BioRobotics Transcript: 46th Annual William Blair Growth Stock Conference - Transcripts
- 6 weeks ago - PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval - GlobeNewsWire
- 2 months ago - AUA Guidelines Strengthen Recommendation for Aquablation® Therapy - GlobeNewsWire